Mandate

Vinge advises Hansa Biopharma in connection with a directed share issue

The board of directors of Hansa Biopharma has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby Hansa Biopharma will raise proceeds of SEK 1.1 billion, before issue costs.

The share issue was made on the basis of an accelerated bookbuilding process carried out by Morgan Stanley, Kempen & Co and Zonda Partners, and was multiple times oversubscribed due to high demand from US, European and Swedish institutional investors.

Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)- mediated autoimmune conditions, transplant rejection and cancer.

Vinge’s team consisted of Dain Hård Nevonen, Malte St Cyr Ohm, Stephanie Stiernstedt and Hampus Olsson.

 

Related

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025